Pancreatic Cancer: Daraxonrasib
2026-05-31 · Department of Health and Social Care · HL517 · Official question
Baroness Ritchie of Downpatrick
Question
To ask His Majesty's Government what assessment they have made of the potential for the drug Daraxonrasib to treat advanced pancreatic cancer; and when they expect the National Institute for Health and Care to complete their technology appraisal of the dr
Answer
Daraxonrasib is not currently licensed in the United Kingdom. Should the manufacturer submit an application to the Medicines and Healthcare products Regulatory Agency (MHRA) for a product licence, the MHRA has processes in place to review and assess its b...